Matt Hewitt
Stock Analyst at Craig-Hallum
(3.67)
# 605
Out of 4,825 analysts
42
Total ratings
51.43%
Success rate
7.19%
Average return
Main Sectors:
Stocks Rated by Matt Hewitt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CSBR Champions Oncology | Maintains: Buy | $8 → $12 | $6.66 | +80.18% | 4 | Mar 12, 2025 | |
| CLOV Clover Health Investments | Initiates: Buy | $6 | $3.32 | +80.72% | 1 | Dec 17, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $30 → $32 | $24.61 | +30.03% | 4 | Nov 13, 2024 | |
| OMCL Omnicell | Maintains: Buy | $45 → $64 | $31.45 | +103.50% | 6 | Oct 31, 2024 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $135 → $140 | $110.22 | +27.02% | 3 | Jul 9, 2024 | |
| SLP Simulations Plus | Reiterates: Buy | $56 | $33.75 | +65.93% | 7 | Jul 3, 2024 | |
| NOTV Inotiv | Maintains: Buy | $25 → $10 | $1.96 | +411.51% | 3 | May 16, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $35 → $30 | $24.88 | +20.58% | 3 | May 2, 2024 | |
| MXCT MaxCyte | Initiates: Buy | $7 | $2.80 | +150.00% | 1 | Nov 29, 2023 | |
| RGEN Repligen | Maintains: Buy | $207 → $200 | $137.20 | +45.77% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.76 | +469.80% | 1 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $67 → $30 | $6.97 | +330.42% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $1.26 | +31,646.03% | 1 | Jan 4, 2022 | |
Champions Oncology
Mar 12, 2025
Maintains: Buy
Price Target: $8 → $12
Current: $6.66
Upside: +80.18%
Clover Health Investments
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $3.32
Upside: +80.72%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $30 → $32
Current: $24.61
Upside: +30.03%
Omnicell
Oct 31, 2024
Maintains: Buy
Price Target: $45 → $64
Current: $31.45
Upside: +103.50%
Ligand Pharmaceuticals
Jul 9, 2024
Maintains: Buy
Price Target: $135 → $140
Current: $110.22
Upside: +27.02%
Simulations Plus
Jul 3, 2024
Reiterates: Buy
Price Target: $56
Current: $33.75
Upside: +65.93%
Inotiv
May 16, 2024
Maintains: Buy
Price Target: $25 → $10
Current: $1.96
Upside: +411.51%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $35 → $30
Current: $24.88
Upside: +20.58%
MaxCyte
Nov 29, 2023
Initiates: Buy
Price Target: $7
Current: $2.80
Upside: +150.00%
Repligen
Aug 3, 2023
Maintains: Buy
Price Target: $207 → $200
Current: $137.20
Upside: +45.77%
Apr 13, 2023
Initiates: Buy
Price Target: $10
Current: $1.76
Upside: +469.80%
Apr 28, 2022
Maintains: Hold
Price Target: $67 → $30
Current: $6.97
Upside: +330.42%
Jan 4, 2022
Initiates: Buy
Price Target: $400
Current: $1.26
Upside: +31,646.03%